

JUNE 3-7, 2022

2022 ASCO[®] ANNUAL MEETING

Showcasing Genentech's Commitment to
Innovative Science & Inclusive Research

**SHOWCASING
GENENTECH'S COMMITMENT
TO INNOVATIVE SCIENCE
& INCLUSIVE RESEARCH**

TABLE OF CONTENTS

Select Presentations and Poster Sessions
on Genentech and Roche Molecules

Pg
4

Breast



Pg
10

Melanoma



Pg
5

Genitourinary



Pg
11

Rare Solid Tumor



Pgs
6-8

Hematology



Pg
12

Pan Tumor



Pg
9

Lung




Pg
13

**Publication-only
Abstracts**

- Key abstracts are highlighted in each section.


For abstract presentation date/time, please visit the congress website.



 **ABSTRACT #1515** Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic


Chau T. Dang

Poster Discussion Session: Care Delivery and Regulatory Policy

 **ABSTRACT #589** Neoadjuvant giredestrant (GDC-9545) + palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study

Peter A. Fasching

Poster Session: Breast Cancer—Local/Regional/Adjuvant

 **ABSTRACT #1052** Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with *PIK3CA*-mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC)

Philippe L. Bedard

Poster Session: Breast Cancer—Metastatic

This list is provided courtesy of Genentech, Inc. Genentech is not responsible for any errors contained herein. The ideas and opinions expressed in the abstracts and presentations included in this document do not necessarily reflect those of Genentech. The reader is encouraged to contact the primary authors with questions regarding the content of the abstracts or presentations. Genentech does not assume responsibility for any injury and/or damage to persons or property arising out of or relating to any use of the material contained in this document. The reader is advised to check the appropriate medical literature and the prescribing information provided by the product manufacturer for information about the approved uses of the drug, relevant safety information, and to verify the dosage and method of administration.


 = Oral presentation/poster discussion

 = Poster display

Genentech
A Member of the Roche Group

© 2022 Genentech USA, Inc. All rights reserved. M-US-00015728(v2.0)



 **ABSTRACT #5056** Activation of the AKT pathway and outcomes in patients (pts) treated with or without ipatasertib (ipat) in metastatic castration-resistant prostate cancer (mCRPC): Next-generation sequencing (NGS) data from the phase III IPATential150 trial

Christopher Sweeney

Poster Session: Genitourinary Cancer—Prostate, Testicular, and Penile

This list is provided courtesy of Genentech, Inc. Genentech is not responsible for any errors contained herein. The ideas and opinions expressed in the abstracts and presentations included in this document do not necessarily reflect those of Genentech. The reader is encouraged to contact the primary authors with questions regarding the content of the abstracts or presentations. Genentech does not assume responsibility for any injury and/or damage to persons or property arising out of or relating to any use of the material contained in this document. The reader is advised to check the appropriate medical literature and the prescribing information provided by the product manufacturer for information about the approved uses of the drug, relevant safety information, and to verify the dosage and method of administration.

 = Oral presentation/poster discussion

 = Poster display

Genentech
A Member of the Roche Group


© 2022 Genentech USA, Inc. All rights reserved. M-US-00015728(v2.0)



 **ABSTRACT #7500** Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results


Michael Dickinson

Oral Abstract Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

 **ABSTRACT #7517** Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma (DLBCL) from the POLARIX trial


Franck Morschhauser

Poster Discussion Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

 **ABSTRACT #7526** Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas

Stephen J. Schuster

Poster Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

 **ABSTRACT #7551** Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)

Matthew J. Matasar

Poster Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

This list is provided courtesy of Genentech, Inc. Genentech is not responsible for any errors contained herein. The ideas and opinions expressed in the abstracts and presentations included in this document do not necessarily reflect those of Genentech. The reader is encouraged to contact the primary authors with questions regarding the content of the abstracts or presentations. Genentech does not assume responsibility for any injury and/or damage to persons or property arising out of or relating to any use of the material contained in this document. The reader is advised to check the appropriate medical literature and the prescribing information provided by the product manufacturer for information about the approved uses of the drug, relevant safety information, and to verify the dosage and method of administration.

 = Oral presentation/poster discussion

 = Poster display

Genentech
A Member of the Roche Group


© 2022 Genentech USA, Inc. All rights reserved. M-US-00015728(v2.0)



 **ABSTRACT #7558** Asia subpopulation analysis from the phase III POLARIX trial


Yuqin Song

Poster Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

 **ABSTRACT #7561** Analysis of peripheral neuropathy (PN) using clinician- and patient-reported outcomes (ClinRO and PRO) in the POLARIX study

Marek Trneny

Poster Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

 **ABSTRACT #TPS7588** CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy

Loretta J. Nastoupil

Poster Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

 **ABSTRACT #TPS8069** CAMMA 1: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma

Ravi Vij

Poster Session: Hematologic Malignancies—Plasma Cell Dyscrasia

This list is provided courtesy of Genentech, Inc. Genentech is not responsible for any errors contained herein. The ideas and opinions expressed in the abstracts and presentations included in this document do not necessarily reflect those of Genentech. The reader is encouraged to contact the primary authors with questions regarding the content of the abstracts or presentations. Genentech does not assume responsibility for any injury and/or damage to persons or property arising out of or relating to any use of the material contained in this document. The reader is advised to check the appropriate medical literature and the prescribing information provided by the product manufacturer for information about the approved uses of the drug, relevant safety information, and to verify the dosage and method of administration.


 = Oral presentation/poster discussion

 = Poster display

Genentech
A Member of the Roche Group


© 2022 Genentech USA, Inc. All rights reserved. M-US-00015728(v2.0)




 **ABSTRACT #TPS8070 CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma**

Sosana Delimpasi


Poster Session: Hematologic Malignancies—Plasma Cell Dyscrasia



 **ABSTRACT #LBA8507 SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC)**


Charles M. Rudin

Oral Abstract Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

 **ABSTRACT #LBA9023 Efficacy/safety of entrectinib in patients (pts) with *ROS1*-positive (*ROS1+*) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST)**


Solange Peters

Poster Discussion Session: Lung Cancer—Non-Small Cell Metastatic

 **ABSTRACT #TPS9141 A randomized phase 3 study of entrectinib versus crizotinib in patients (pts) with locally advanced/metastatic *ROS1* fusion-positive (fp) NSCLC with or without baseline CNS metastases (mets)**

Anne-Marie C. Dingemans

Poster Session: Lung Cancer—Non-Small Cell Metastatic

 **ABSTRACT #TPS9159 AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with *RET* fusion-positive advanced/metastatic NSCLC**

Sanjay Popat

Poster Session: Lung Cancer—Non-Small Cell Metastatic

This list is provided courtesy of Genentech, Inc. Genentech is not responsible for any errors contained herein. The ideas and opinions expressed in the abstracts and presentations included in this document do not necessarily reflect those of Genentech. The reader is encouraged to contact the primary authors with questions regarding the content of the abstracts or presentations. Genentech does not assume responsibility for any injury and/or damage to persons or property arising out of or relating to any use of the material contained in this document. The reader is advised to check the appropriate medical literature and the prescribing information provided by the product manufacturer for information about the approved uses of the drug, relevant safety information, and to verify the dosage and method of administration.

 = Oral presentation/poster discussion

 = Poster display

Genentech
A Member of the Roche Group

© 2022 Genentech USA, Inc. All rights reserved. M-US-00015728(v2.0)

This list is provided courtesy of Genentech, Inc. Genentech is not responsible for any errors contained herein. The ideas and opinions expressed in the abstracts and presentations included in this document do not necessarily reflect those of Genentech. The reader is encouraged to contact the primary authors with questions regarding the content of the abstracts or presentations. Genentech does not assume responsibility for any injury and/or damage to persons or property arising out of or relating to any use of the material contained in this document. The reader is advised to check the appropriate medical literature and the prescribing information provided by the product manufacturer for information about the approved uses of the drug, relevant safety information, and to verify the dosage and method of administration.


 = Oral presentation/poster discussion

 = Poster display

Genentech
A Member of the Roche Group

© 2022 Genentech USA, Inc. All rights reserved. M-US-00015728(v2.0)



 **ABSTRACT #9515** Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with *BRAF*^{V600} mutation–positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study

Reinhard Dummer

Oral Abstract Session: Melanoma/Skin Cancers

 **ABSTRACT #9547** Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in *BRAF*^{V600} mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study

Grant A. McArthur

Poster Session: Melanoma/Skin Cancers

 **ABSTRACT #6080** Pralsetinib in patients (pts) with advanced or metastatic *RET*-altered thyroid cancer (TC): Updated data from the ARROW trial

Aaron Scott Mansfield

Poster Session: Head and Neck Cancer

This list is provided courtesy of Genentech, Inc. Genentech is not responsible for any errors contained herein. The ideas and opinions expressed in the abstracts and presentations included in this document do not necessarily reflect those of Genentech. The reader is encouraged to contact the primary authors with questions regarding the content of the abstracts or presentations. Genentech does not assume responsibility for any injury and/or damage to persons or property arising out of or relating to any use of the material contained in this document. The reader is advised to check the appropriate medical literature and the prescribing information provided by the product manufacturer for information about the approved uses of the drug, relevant safety information, and to verify the dosage and method of administration.

 = Oral presentation/poster discussion

 = Poster display

Genentech
A Member of the Roche Group

© 2022 Genentech USA, Inc. All rights reserved. M-US-00015728(v2.0)

This list is provided courtesy of Genentech, Inc. Genentech is not responsible for any errors contained herein. The ideas and opinions expressed in the abstracts and presentations included in this document do not necessarily reflect those of Genentech. The reader is encouraged to contact the primary authors with questions regarding the content of the abstracts or presentations. Genentech does not assume responsibility for any injury and/or damage to persons or property arising out of or relating to any use of the material contained in this document. The reader is advised to check the appropriate medical literature and the prescribing information provided by the product manufacturer for information about the approved uses of the drug, relevant safety information, and to verify the dosage and method of administration.

 = Oral presentation/poster discussion

 = Poster display

Genentech
A Member of the Roche Group


© 2022 Genentech USA, Inc. All rights reserved. M-US-00015728(v2.0)



 **ABSTRACT #2519** Identifying mechanisms of acquired immune escape from sequential, paired biopsies

F. Steven Hodi

Poster Discussion Session: Developmental Therapeutics—Immunotherapy

 **ABSTRACT #3099** Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic *NTRK* fusion-positive (*NTRK*-fp) solid tumors

Maciej Jerzy Krzakowski

Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

This list is provided courtesy of Genentech, Inc. Genentech is not responsible for any errors contained herein. The ideas and opinions expressed in the abstracts and presentations included in this document do not necessarily reflect those of Genentech. The reader is encouraged to contact the primary authors with questions regarding the content of the abstracts or presentations. Genentech does not assume responsibility for any injury and/or damage to persons or property arising out of or relating to any use of the material contained in this document. The reader is advised to check the appropriate medical literature and the prescribing information provided by the product manufacturer for information about the approved uses of the drug, relevant safety information, and to verify the dosage and method of administration.

 = Oral presentation/poster discussion

 = Poster display

Genentech
A Member of the Roche Group

© 2022 Genentech USA, Inc. All rights reserved. M-US-00015728(v2.0)

Clinical characteristics and real-world progression-free survival (rwPFS) of patients with HER2-positive and hormone receptor (HR)-positive metastatic breast cancer (MBC) initiating endocrine therapy (ET) in combination with the first line of treatment: An analysis of electronic health records in the United States

Thibaut Sanglier

Describing U.S. real-world patients (pts) with hormone receptor-positive early breast cancer (HR+ EBC) by risk status

Mary K. Downer

Diversity, inclusion, and patient (pt)-centricity in the randomized, double-blind, phase III ASTEFANIA study of ado-trastuzumab emtansine (T-DM1) ± atezolizumab in pts with HER2-positive early breast cancer (EBC) with residual invasive disease after preoperative chemotherapy and anti-HER2 therapy

Sarah Rogerson

The impact of neoadjuvant treatment (NAT) on surgery in early breast cancer (EBC): A real-world data study

Thibaut Sanglier

This list is provided courtesy of Genentech, Inc. Genentech is not responsible for any errors contained herein. The ideas and opinions expressed in the abstracts and presentations included in this document do not necessarily reflect those of Genentech. The reader is encouraged to contact the primary authors with questions regarding the content of the abstracts or presentations. Genentech does not assume responsibility for any injury and/or damage to persons or property arising out of or relating to any use of the material contained in this document. The reader is advised to check the appropriate medical literature and the prescribing information provided by the product manufacturer for information about the approved uses of the drug, relevant safety information, and to verify the dosage and method of administration.

 = Oral presentation/poster discussion

 = Poster display

Genentech
A Member of the Roche Group

© 2022 Genentech USA, Inc. All rights reserved. M-US-00015728(v2.0)

